FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2156161928> ?p ?o ?g. }

• W2156161928 endingPage "53" @default.
• W2156161928 startingPage "1347" @default.
• W2156161928 abstract "In order to assess the role of the combination of low-dose cytarabine (Ara-C) plus aclarubicin (CA) in remission induction for patients with untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), we retrospectively analyzed the efficacy and safety of CA.Data of twenty patients with untreated AML or high-risk MDS who were ineligible for standard-dose Ara-C plus anthracycline and received CA as remission-induction therapy were analyzed. CA consisted of low-dose Ara-C (10 mg/m(2), subcutaneous injection every 12 hours, for 14 days) and aclarubicin (14 mg/m(2) for patients <70 years old and 10 mg/m(2) for patients ≥70 years old in a one-hour infusion for 4 days). Granulocyte colony-stimulating factor (G-CSF) was used from day 1 of CA to white blood cell count (WBC) recovery, except for patients with initial WBC of more than 20.0×10(3)/mm(3).Eleven patients (55%) achieved complete remission. All four patients whose WBC were ≥20.0×10(3)/mm(3) and did not receive G-CSF were refractory to CA. The predicted 2-year overall survival rate and median survival duration of all 20 patients were 37.9% and 363 days, respectively. The predicted 1-year relapse-free survival (RFS) rate and median duration of RFS of 11 patients who achieved complete remission were 30.3% and 332 days, respectively. Only one patient died due to transfusion-related acute lung injury. No patients died due to severe infections.CA combination with G-CSF as remission-induction therapy is promising and well-tolerated in patients with previously untreated AML or high-risk MDS who are ineligible for standard-dose Ara-C plus anthracycline without leukocytosis. In order to improve RFS, intensive postremission chemotherapy or allogeneic hematopoietic stem cell transplantation should be introduced." @default.
• W2156161928 created "2016-06-24" @default.
• W2156161928 creator A5003204127 @default.
• W2156161928 creator A5014411218 @default.
• W2156161928 creator A5019926116 @default.
• W2156161928 creator A5020613096 @default.
• W2156161928 creator A5022142826 @default.
• W2156161928 creator A5026171706 @default.
• W2156161928 creator A5046753801 @default.
• W2156161928 creator A5061841627 @default.
• W2156161928 creator A5069916638 @default.
• W2156161928 creator A5073388784 @default.
• W2156161928 creator A5076825516 @default.
• W2156161928 creator A5077950778 @default.
• W2156161928 creator A5078409741 @default.
• W2156161928 creator A5090521080 @default.
• W2156161928 creator A5091657418 @default.
• W2156161928 date "2012-04-01" @default.
• W2156161928 modified "2023-09-23" @default.
• W2156161928 title "Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline." @default.
• W2156161928 cites W1534965621 @default.
• W2156161928 cites W1572539757 @default.
• W2156161928 cites W1832802185 @default.
• W2156161928 cites W1834277939 @default.
• W2156161928 cites W1860225788 @default.
• W2156161928 cites W1976112739 @default.
• W2156161928 cites W2019233508 @default.
• W2156161928 cites W2029502691 @default.
• W2156161928 cites W2041988411 @default.
• W2156161928 cites W2051987542 @default.
• W2156161928 cites W2058188142 @default.
• W2156161928 cites W2068556430 @default.
• W2156161928 cites W2079025304 @default.
• W2156161928 cites W2080799966 @default.
• W2156161928 cites W2091335554 @default.
• W2156161928 cites W2092449369 @default.
• W2156161928 cites W2109065151 @default.
• W2156161928 cites W2112998845 @default.
• W2156161928 cites W2116858301 @default.
• W2156161928 cites W2133650635 @default.
• W2156161928 cites W2141129374 @default.
• W2156161928 cites W2148921332 @default.
• W2156161928 cites W2979853770 @default.
• W2156161928 cites W55108809 @default.
• W2156161928 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22493369" @default.
• W2156161928 hasPublicationYear "2012" @default.
• W2156161928 type Work @default.
• W2156161928 sameAs 2156161928 @default.
• W2156161928 citedByCount "5" @default.
• W2156161928 countsByYear W21561619282016 @default.
• W2156161928 countsByYear W21561619282017 @default.
• W2156161928 countsByYear W21561619282021 @default.
• W2156161928 crossrefType "journal-article" @default.
• W2156161928 hasAuthorship W2156161928A5003204127 @default.
• W2156161928 hasAuthorship W2156161928A5014411218 @default.
• W2156161928 hasAuthorship W2156161928A5019926116 @default.
• W2156161928 hasAuthorship W2156161928A5020613096 @default.
• W2156161928 hasAuthorship W2156161928A5022142826 @default.
• W2156161928 hasAuthorship W2156161928A5026171706 @default.
• W2156161928 hasAuthorship W2156161928A5046753801 @default.
• W2156161928 hasAuthorship W2156161928A5061841627 @default.
• W2156161928 hasAuthorship W2156161928A5069916638 @default.
• W2156161928 hasAuthorship W2156161928A5073388784 @default.
• W2156161928 hasAuthorship W2156161928A5076825516 @default.
• W2156161928 hasAuthorship W2156161928A5077950778 @default.
• W2156161928 hasAuthorship W2156161928A5078409741 @default.
• W2156161928 hasAuthorship W2156161928A5090521080 @default.
• W2156161928 hasAuthorship W2156161928A5091657418 @default.
• W2156161928 hasConcept C121608353 @default.
• W2156161928 hasConcept C126322002 @default.
• W2156161928 hasConcept C141071460 @default.
• W2156161928 hasConcept C2776694085 @default.
• W2156161928 hasConcept C2776802502 @default.
• W2156161928 hasConcept C2777767877 @default.
• W2156161928 hasConcept C2778041864 @default.
• W2156161928 hasConcept C2778461978 @default.
• W2156161928 hasConcept C2778488018 @default.
• W2156161928 hasConcept C2778729363 @default.
• W2156161928 hasConcept C2780007613 @default.
• W2156161928 hasConcept C2780817109 @default.
• W2156161928 hasConcept C2780847677 @default.
• W2156161928 hasConcept C530470458 @default.
• W2156161928 hasConcept C71924100 @default.
• W2156161928 hasConcept C90924648 @default.
• W2156161928 hasConceptScore W2156161928C121608353 @default.
• W2156161928 hasConceptScore W2156161928C126322002 @default.
• W2156161928 hasConceptScore W2156161928C141071460 @default.
• W2156161928 hasConceptScore W2156161928C2776694085 @default.
• W2156161928 hasConceptScore W2156161928C2776802502 @default.
• W2156161928 hasConceptScore W2156161928C2777767877 @default.
• W2156161928 hasConceptScore W2156161928C2778041864 @default.
• W2156161928 hasConceptScore W2156161928C2778461978 @default.
• W2156161928 hasConceptScore W2156161928C2778488018 @default.
• W2156161928 hasConceptScore W2156161928C2778729363 @default.
• W2156161928 hasConceptScore W2156161928C2780007613 @default.
• W2156161928 hasConceptScore W2156161928C2780817109 @default.
• W2156161928 hasConceptScore W2156161928C2780847677 @default.
• W2156161928 hasConceptScore W2156161928C530470458 @default.

• next